176 related articles for article (PubMed ID: 32684738)
1. Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.
Warnecke-Eberz U; Plum P; Schweinsberg V; Drebber U; Bruns CJ; Müller DT; Hölscher AH; Bollschweiler E
World J Gastroenterol; 2020 Jun; 26(23):3236-3248. PubMed ID: 32684738
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response.
Odenthal M; Bollschweiler E; Grimminger PP; Schröder W; Brabender J; Drebber U; Hölscher AH; Metzger R; Vallböhmer D
Int J Cancer; 2013 Nov; 133(10):2454-63. PubMed ID: 23649428
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
Saigusa S; Mohri Y; Ohi M; Toiyama Y; Ishino Y; Okugawa Y; Tanaka K; Inoue Y; Kusunoki M
Oncol Rep; 2011 Nov; 26(5):1069-74. PubMed ID: 21811761
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
[TBL] [Abstract][Full Text] [Related]
6. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
7. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
[TBL] [Abstract][Full Text] [Related]
9. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
10. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.
Slotta-Huspenina J; Drecoll E; Feith M; Habermehl D; Combs S; Weichert W; Bettstetter M; Becker K; Langer R
J Transl Med; 2018 Apr; 16(1):109. PubMed ID: 29695253
[TBL] [Abstract][Full Text] [Related]
12. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
13. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
Niwa Y; Yamada S; Sonohara F; Kurimoto K; Hayashi M; Tashiro M; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
J Transl Med; 2019 Jan; 17(1):1. PubMed ID: 30602370
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
15. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma.
Ma W; Wang K; Yang S; Wang J; Tan B; Bai B; Wang N; Jia Y; Jia M; Cheng Y
Int J Clin Exp Pathol; 2014; 7(5):2361-71. PubMed ID: 24966946
[TBL] [Abstract][Full Text] [Related]
18. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
19. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis on potential new molecular targets for esophageal cancer.
Maurer J; Schöpp M; Thurau K; Haier J; Köhler G; Hummel R
Dis Esophagus; 2014 Jan; 27(1):93-100. PubMed ID: 23551625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
